Zura Bio Limited (NASDAQ:ZURA) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Zura Bio Limited (NASDAQ:ZURA) have been given a consensus rating of “Buy” by the seven brokerages that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $15.80.

Several research analysts have weighed in on ZURA shares. Leerink Partners initiated coverage on Zura Bio in a research note on Monday, November 4th. They issued an “outperform” rating and a $15.00 target price on the stock. HC Wainwright restated a “neutral” rating and set a $5.00 price objective on shares of Zura Bio in a research report on Tuesday, December 24th. Leerink Partnrs raised shares of Zura Bio to a “strong-buy” rating in a report on Monday, November 4th. Cantor Fitzgerald reissued an “overweight” rating on shares of Zura Bio in a report on Wednesday, December 11th. Finally, Chardan Capital lowered their price objective on Zura Bio from $14.00 to $12.00 and set a “buy” rating on the stock in a report on Friday, November 8th.

Insider Activity at Zura Bio

In other news, Director Parvinder Thiara sold 1,001,633 shares of the firm’s stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $2.73, for a total value of $2,734,458.09. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 22.10% of the company’s stock.

Institutional Trading of Zura Bio

Hedge funds have recently made changes to their positions in the company. AQR Capital Management LLC acquired a new position in Zura Bio during the 2nd quarter valued at about $43,000. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in shares of Zura Bio during the third quarter worth approximately $46,000. SG Americas Securities LLC boosted its position in Zura Bio by 51.6% during the fourth quarter. SG Americas Securities LLC now owns 23,005 shares of the company’s stock valued at $58,000 after purchasing an additional 7,828 shares during the last quarter. Renaissance Technologies LLC grew its stake in shares of Zura Bio by 51.3% in the 2nd quarter. Renaissance Technologies LLC now owns 17,400 shares of the company’s stock valued at $61,000 after buying an additional 5,900 shares in the last quarter. Finally, Valence8 US LP bought a new position in Zura Bio during the third quarter valued at about $71,000. Hedge funds and other institutional investors own 61.14% of the company’s stock.

Zura Bio Stock Performance

Shares of ZURA opened at $1.77 on Friday. The firm’s fifty day simple moving average is $2.68 and its 200-day simple moving average is $3.51. Zura Bio has a twelve month low of $1.76 and a twelve month high of $6.35.

Zura Bio (NASDAQ:ZURA) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.12). Sell-side analysts anticipate that Zura Bio will post -0.65 earnings per share for the current fiscal year.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.